CLAIMS

Please cancel claims 1-11 and 20-30.

Please add the following new claims 31-51:

31. (New) A method of reducing gastric motility in a subject comprising administering to said subject a therapeutically effective amount of an exendin or an exendin agonist.

32. (New) A method of delaying gastric emptying in a subject comprising administering to said subject a therapeutically effective amount of an exendin or an exendin agonist.

33. (New) A method of reducing gastric motility in a subject comprising administering to said subject an amount of an exendin or an exendin agonist effective for reducing gastric motility.

34. (New) A method of delaying gastric emptying in a subject comprising administering to said subject an amount of an exendin or an exendin agonist effective for delaying gastric emptying.

35. (New) The method according to claim 31, 32, 33 or 34 wherein said exendin is exendin 3.

36. (New) The method according to claim 31, 32, 33 or 34 wherein said exendin is exendin-4.

37. (New) The method according to claim 31, 32, 33 or 34 wherein said subject is undergoing a gastrointestinal diagnostic procedure.

38. (New) The method according to claim 37 wherein said gastrointestinal diagnostic procedure is a radiological examination.

39. (New) The method according to claim 38 wherein said gastrointestinal diagnostic procedure is magnetic resonance imaging.

40. (New) A method according to claim 31 or 33 wherein said gastric motility is associated with a gastrointestinal disorder.

41. (New) The method according to claim 31, 32, 33 or 34 wherein said exendin agonist is selected from a peptide compound of the formula [SEQ. ID. NO. 38]:

1 5 10

Xaa_1 Xaa_2 Xaa_3 Gly Thr Xaa_4 Xaa_5 Xaa_6 Xaa_7 Xaa_8

15 20

Ser Lys Gln Xaa_9 Glu Glu Glu Ala Val Arg Leu

25 30

Xaa_{10} Xaa_{11} Xaa_{12} Xaa_{13} Leu Lys Asn Gly Gly Xaa_{14}

35

Ser Ser Gly Ala Xaa_{15} Xaa_{16} Xaa_{17} Xaa_{18} -Z

wherein:

D2

Xaa_1 is His, Arg or Tyr;

Xaa_2 is Ser, Gly, Ala or Thr;

Xaa_3 is Asp or Glu;

Xaa_4 is Phe, Tyr or naphthylalanine;

Xaa_5 is Thr or Ser;

Xaa_6 is Ser or Thr;

Xaa_7 is Asp or Glu;

Xaa_8 is Leu, Ile, Val, pentylglycine or Met;

Xaa_9 is Leu, Ile, pentylglycine, Val or Met;

Xaa_{10} is Phe, Tyr or naphthylalanine;

Xaa_{11} is Ile, Val, Leu, pentylglycine, tert-butylglycine or Met;

Xaa_{12} is Glu or Asp;

Xaa_{13} is Trp, Phe, Tyr, or naphthylalanine;

Xaa_{14} ,Xaa_{15} , Xaa_{16} and Xaa_{17} are independently Pro, homoproline, 3Hyp, 4Hyp, thioproline, N-alkylglycine, N-alkylpentylglycine or N-alkylalanine;

Xaa_{18} is Ser, Thr or Tyr; and

Z is –OH or $–NH_2$;

with the proviso that the compound does not have the formula of either exendin-3 [SEQ. ID. NO. 1] or exendin-4 [SEQ. ID. NO. 2] and pharmaceutically acceptable salts thereof.

42. (New) The method according to claim 31, 32, 33 or 34 wherein said exendin agonist is selected from a peptide compound of the formula [SEQ. ID. NO. 39]:

1 5 10

Xaa_1 Xaa_2 Xaa_3 Gly Thr Xaa_4 Xaa_5 Xaa_6 Xaa_7 Xaa_8

15 20

Ser Lys Gln Xaa_9 Glu Glu Glu Ala Val Arg Leu

25 30

Xaa_{10} Xaa_{11} Xaa_{12} Xaa_{13} Leu Lys Asn Gly Gly Xaa_{14}

35

Ser Ser Gly Ala Xaa_{15} Xaa_{16} Xaa_{17} Xaa_{18} -Z

D2

wherein:

Xaa_1 is His or Arg;

Xaa_2 is Ser or Gly;

Xaa_3 is Asp or Glu;

Xaa_4 is Phe or naphthylalanine;

Xaa_5 is Thr or Ser;

Xaa_6 is Ser or Thr;

Xaa_7 is Asp or Glu;

Xaa_8 is Leu or pentylglycine

Xaa_9 is Leu or pentylglycine;

Xaa_{10} is Phe or naphthylalanine;

Xaa_{11} is Ile, Val or tert-butylglycine;

Xaa_{12} is Glu or Asp;

Xaa_{13} is Trp or Phe;

Xaa_{14} , Xaa_{15}, Xaa_{16} and Xaa_{17} are independently selected from Pro, homoproline, thioproline or N-methylalanine;

Xaa_{18} is Ser or Tyr; and

Z is –OH or $–NH_2$;

with the proviso that the compound does not have the formula of either exendin-3 [SEQ. ID.

NO. 1] or exendin-4 [SEQ. ID. NO. 2] and pharmaceutically acceptable salts thereof.

43. (New) The method of any of claims 31, 32, 33 or 34, wherein said exendin agonist is an exendin analog or derivative.

44. (New) The method of claim 43, wherein said exendin analog or derivative has an activity about 1% to about 10,000% of the activity of the exendin of which it is an analog or derivative.

45. (New) The method of claim 43, wherein said exendin analog or derivative has an activity about 10% to about 1,000% of the activity of the exendin of which it is an analog or derivative.

D2

46. (New) The method of claim 43, wherein said exendin analog or derivative has an activity about 50% to about 500% of the activity of the exendin of which it is an analog or derivative.

47. (New) The method of claim 43, wherein said exendin analog or derivative has at least about 50% amino acid sequence similarity to the exendin of which it is an analog or derivative.

48. (New) The method of claim 43, wherein said exendin analog or derivative has at least about 70% amino acid sequence similarity to the exendin of which it is an analog or derivative.

49. (New) The method of claim 43, wherein said exendin analog or derivative has at least about 90% amino acid sequence similarity to the exendin of which it is an analog or derivative.

50. (New) The method of claim 43, wherein said exendin analog or derivative has at least about 95% amino acid sequence similarity to the exendin of which it is an analog or derivative.

51. (New) The method of claim 43, wherein said exendin analog or derivative is an analog or derivative of exendin-4.